Device Trial Radar · NCT06073535
The Use of Injectable-Platelet Rich Fibrin (i-PRF) in the Lower Third Molar Extraction
Last checked: Nov 20, 2026Latest source record: Dec 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
40
Actual
Start
Feb 27, 2023
Primary completion
Sep 4, 2023
Study completion Dec 29, 2023
Sponsor
- Lead sponsor
- University of NaplesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 10, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 35 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Lower third molar extraction is one of the most frequently performed surgical procedures in dentistry. Common sequelae, including pain, swelling and trismus, can severely affect patients' quality of life during the immediate postoperative period. The aim of this randomized-controlled trial is to clinically evaluate the reduction of lower third molar extraction-related complications, such as swelling and pain, and wound healing, following submucosal infiltration of injectable platelet rich fibrin.
Conditions
- Molar, Third
- Postoperative Complications
Interventions
Extraction of mandibular third molarProcedure
After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle. An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary.
i-PRFDevice
20 ml of venous blood will be drawn from the ante-cubital vein of all patients and collected in 2 plastic tubes (Vacutainer, Becton\& Dickinson, Rutherford, NJ) containing no anticoagulant or gelling agent. The tubes will be placed in a centrifuge (DUO Centrifuge, Nice, France) at 700 round per minute for 3 min, at the end of which time the blood will be separated into 2 fractions: the layer of injectable liquid i-PRF, which is more superficial, and the layer of red blood cells, in the deep part. From each tube, i-PRF will be withdrawn using a sterile syringe and it will be infiltrated into the lesion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Postoperative swellingTime frame: Measurements will be taken before surgery, on day 3 and day 7.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gilberto Sammartino
Naples, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.